ZURICH, SWITZERLAND – EQS Newswire – March 11, 2020 – Xlife Sciences AG tests a new therapy for the treatment of pneumonia caused by coronavirus in cooperation with the Institute of Virology and Immunology (IVI) of the Vetsuisse Faculty of the University of Bern in Switzerland. Advantages of the therapy are a fundamentally better biovariability and a broad target diversity. The necessary documents have successfully been submitted.
Xlife Sciences AG (m:access: XLS) is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage.
Key takeaways:Tonbo Imaging shares listed at a 66% premium over their IPO price on both…
Key takeaways:GIFT Nifty broke the 61.8% Fibonacci retracement level, and analysts tracking the move set…
Key takeaways:October 26, 2026 is a holiday in parts of India: banks in states observing…
Key takeaways:Oil prices jumped about $3 in a single session to their highest settlement since…
Key takeaways:The Detroit Pistons and Philadelphia 76ers meet on October 25, 2026, per The New…
Key takeaways:Lamine Yamal, a Barcelona winger who came through La Masia, is trending in football…